Trulicity Cost in New Mexico 2026: Prices, Medicaid, and Savings Options

What Does Trulicity Actually Cost in New Mexico in 2026?

The Eli Lilly manufacturer list price for Trulicity is $931 per month regardless of dose or pen count, and that figure holds at retail pharmacies across New Mexico in 2026. Cash-pay patients without manufacturer assistance pay close to that number. Insurance negotiated rates vary, but uninsured New Mexicans should expect $900 to $950 at most chain and independent pharmacies without a discount program.

Trulicity is available as dulaglutide 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg single-dose pens, each dispensed in a four-pen (four-week) carton [1]. The FDA approved dulaglutide in September 2014 for glycemic control in adults with type 2 diabetes, and a cardiovascular risk-reduction indication followed in 2020 based on the REWIND trial [2]. That cardiovascular indication matters for New Mexico patients with established heart disease because it expands the medical justification for coverage appeals.

GoodRx and similar pharmacy-benefit aggregators list New Mexico cash prices between $850 and $931 depending on specific pharmacy, but these prices shift with contract renegotiations and should be verified at the point of dispensing [3]. The $931 list price is set by Eli Lilly and is not discounted at the pharmacy counter without a coupon, savings card, or insurance plan.

Dose escalation also affects cost. Patients who titrate from 0.75 mg to 4.5 mg over several months still pay one carton price per month, because each pen strength is sold as a four-pack at the same list price. One 2023 analysis in Diabetes Care found that GLP-1 receptor agonist list prices increased at roughly 5% annually between 2014 and 2023, making early enrollment in savings programs financially significant [4].

Does New Mexico Medicaid Cover Trulicity?

New Mexico Medicaid (Centennial Care) does not cover Trulicity (dulaglutide) for type 2 diabetes as of 2026. Formulary exclusions for branded GLP-1 receptor agonists are common across state Medicaid programs due to cost-effectiveness thresholds, and New Mexico follows this pattern [5].

Medicaid enrollees have two realistic paths. First, a prescribing physician can submit a prior authorization (PA) request citing comorbid cardiovascular disease, failure of at least two preferred oral agents, and documented A1C above 9%. Approval rates for PA overrides in NM Centennial Care are low for Trulicity specifically, but a formal denial generates a denial letter that supports a subsequent appeal or a manufacturer patient-assistance application. Second, patients who qualify for Lilly's patient-assistance program (Lilly Cares) may receive dulaglutide at no cost if household income is at or below 400% of the federal poverty level [6].

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, independent of A1C [7]. That guideline language is a direct basis for a PA clinical justification letter. A board-certified endocrinologist or cardiologist co-signing the PA request increases approval odds.

New Mexico Children's Medicaid (CHIP) formularies are separate. Dulaglutide is not FDA-approved for patients under 18, so pediatric CHIP coverage is not applicable [1].

Is Compounded Dulaglutide Legal in New Mexico?

Compounded dulaglutide is available through licensed 503A compounding pharmacies operating in New Mexico, but the legal status is tied to strict conditions that patients and prescribers must understand.

Section 503A of the Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs based on a valid patient-specific prescription when the finished drug is not commercially available in the required form or strength [8]. Because Eli Lilly's Trulicity is commercially available and FDA-approved, compounded dulaglutide occupies a narrow legal space: it may be prepared only when the commercial product is unavailable, back-ordered, or when a patient has a documented allergy to an excipient in the branded pen that the compounder can omit [8].

The FDA issued a 503A compounding policy update in 2024 that explicitly noted dulaglutide is not on the FDA's 503A bulk-drug substances list, meaning it cannot be compounded from bulk API under standard 503A authority [9]. This is a different situation from semaglutide, which was on the shortage list. New Mexico patients who see telehealth platforms advertising "compounded dulaglutide" at near-zero cost should verify that the compounding pharmacy holds a current NM Board of Pharmacy 503A license and that the prescription is patient-specific [10].

A licensed New Mexico 503A pharmacy may still produce a modified formulation (for example, a vial form for patients who cannot use the auto-injector pen) if a legitimate clinical need is documented. The prescriber carries legal responsibility for the clinical justification. Patients should request a certificate of analysis for any compounded product.

Which Insurance Plans Cover Trulicity in New Mexico?

Commercial insurance coverage for Trulicity in New Mexico varies by plan tier, formulary year, and whether the patient carries a diabetes diagnosis versus an obesity-only diagnosis.

Most Blue Cross Blue Shield of New Mexico commercial plans place Trulicity on Tier 3 (preferred brand) with a $60 to $150 copay after meeting the deductible, though exact amounts depend on the specific employer plan design [11]. Presbyterian Health Plan and Molina Healthcare of New Mexico (commercial, not Medicaid) list dulaglutide on their formularies with PA requirements tied to documented type 2 diabetes and A1C above 7.5% [12].

Medicare Part D coverage for Trulicity depends on the specific Part D plan. Because dulaglutide carries both a diabetes and a cardiovascular indication, many Part D plans include it on Tier 3 or Tier 4 [13]. The Medicare Prescription Payment Plan (M3P), which launched in 2025, allows Part D enrollees to cap out-of-pocket costs at $2,000 annually. For a patient paying $931/month list price, that cap is relevant after the first two months of the plan year.

ACA marketplace plans sold on New Mexico's beWellnm exchange are required to cover prescription drugs, but formulary placement of Trulicity is plan-specific. Silver-level plans in NM typically require PA for any GLP-1 agent [14]. Patients should call the plan's pharmacy benefits line before filling to confirm Tier placement and confirm whether the Lilly savings card can be stacked on top of plan cost-sharing.

Key steps for insurance coverage in New Mexico:

1. Obtain an A1C result and a confirmed type 2 diabetes diagnosis in the medical record.
2. Ask the prescriber to document at least one trial of metformin (usually 90 days at therapeutic dose) unless contraindicated.
3. Request a formal PA from the prescriber's office before the first fill.
4. If denied, file an appeal citing the 2024 ADA Standards of Care [7] and, if applicable, the REWIND cardiovascular outcomes data [2].

The REWIND Trial: Why Dulaglutide's Evidence Base Matters for Coverage

The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes across 24 countries and followed them for a median of 5.4 years [2]. Dulaglutide 1.5 mg once weekly reduced the primary composite endpoint of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or cardiovascular death) in 12.0% of participants versus 13.4% in the placebo group, a hazard ratio of 0.88 (95% CI 0.79 to 0.99, P<0.026) [2].

REWIND was notable because 69% of its participants had no prior cardiovascular disease at baseline, only a risk factor profile. That design makes the trial more representative of primary-prevention patients, a distinction that strengthens the argument for coverage in NM patients who do not yet have established ASCVD [15].

A secondary analysis published in The Lancet Diabetes and Endocrinology found that dulaglutide reduced the rate of new or worsening nephropathy by 15% compared to placebo (HR 0.85 to 95% CI 0.77 to 0.93) [16]. For New Mexico patients, where chronic kidney disease prevalence among adults with diabetes is approximately 30%, this renal endpoint is clinically and financially meaningful because CKD complications drive hospitalizations.

The FDA updated the Trulicity prescribing information in 2020 to reflect the cardiovascular risk-reduction indication based on REWIND [1]. That label change directly enables prescribers to cite REWIND data in prior authorization letters to NM commercial and Medicare Part D plans.

The Eli Lilly Savings Card and Patient Assistance Programs

Eli Lilly offers two main cost-reduction programs for Trulicity that apply to New Mexico residents.

Lilly Savings Card. Commercially insured patients may pay as little as $25 per month for Trulicity with the Lilly Savings Card. The card applies to out-of-pocket costs (copays and deductibles) but cannot be used by patients enrolled in any federal or state government health program, including Medicare, Medicaid, TRICARE, or VA benefits [6]. New Mexico patients on Centennial Care Medicaid are therefore ineligible. The card is available at LillyCares.com and can be activated online or by phone.

Lilly Cares Foundation Patient Assistance Program. Uninsured or underinsured New Mexicans with household incomes at or below 400% of the federal poverty level (roughly $58,320 for a single adult in 2025) may qualify to receive Trulicity at no cost through the Lilly Cares Foundation [6]. The application requires income documentation, a signed prescription, and a treating physician's attestation. Processing takes two to four weeks. Patients already enrolled should reapply annually because income thresholds update each year with federal poverty guideline changes.

A 2022 study in JAMA Internal Medicine found that manufacturer patient-assistance programs reduced out-of-pocket GLP-1 costs by an average of 73% for enrolled participants, but enrollment rates remained below 30% among eligible uninsured patients because of documentation burden [17]. New Mexico's community health centers (FQHCs), including those operated by First Choice Community Healthcare in Albuquerque, often have patient navigators who assist with PAP enrollment at no cost to the patient.

GoodRx coupons for dulaglutide may lower the cash price to $830 to $900 at select NM pharmacies, but these coupons cannot be combined with insurance and do not substitute for manufacturer assistance for patients who qualify [3].

Telehealth Prescribing of Trulicity in New Mexico

Telehealth prescribing of Trulicity is fully legal in New Mexico as of 2026. New Mexico statute (NMSA 1978, Section 24-25) permits prescribing via synchronous audio-video telehealth after a valid patient-provider relationship is established, and dulaglutide is not a controlled substance, so the DEA's telemedicine prescribing restrictions do not apply [18].

A New Mexico-licensed prescriber (MD, DO, NP, or PA with prescriptive authority) can evaluate a patient via telehealth, order an A1C and fasting glucose, and issue a Trulicity prescription electronically. The prescription can be sent to any licensed pharmacy in New Mexico or to a mail-order pharmacy licensed in NM [18].

HealthRX clinicians operating in New Mexico follow a structured intake process: review of current A1C, eGFR (dulaglutide dose adjustment is not required for renal impairment, but CKD staging informs the clinical picture), body weight, and cardiovascular history before prescribing. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are not candidates for dulaglutide per the FDA black-box warning [1].

The HealthRX telehealth prescribing framework for dulaglutide in New Mexico requires three data points before the first prescription is issued: (1) a confirmed type 2 diabetes diagnosis with A1C above 7.0% on at least one documented lab within 12 months, (2) documentation that metformin was trialed or is contraindicated, and (3) a blood pressure reading and resting heart rate from within 90 days. This mirrors the ADA 2024 Standards of Care algorithm for intensification of glucose-lowering therapy [7].

Side Effects That May Affect Adherence and Cost in New Mexico

Adherence directly affects cost efficiency. A patient who discontinues Trulicity after eight weeks due to nausea has spent $466 with no glycemic benefit.

The most common adverse effects of dulaglutide are gastrointestinal: nausea (12.4% vs. 5.3% placebo in key AWARD trials), diarrhea (8.9%), and vomiting (5.8%) [1]. These effects are typically worst in the first four weeks and attenuate with the slow dose-escalation schedule starting at 0.75 mg for four weeks before advancing to 1.5 mg [1].

A 2021 meta-analysis in Diabetes, Obesity and Metabolism covering 24 randomized controlled trials (N=17,432) found that GI adverse events led to discontinuation in 4.1% of dulaglutide-treated patients versus 1.9% for placebo [19]. Prescribers can reduce discontinuation by counseling patients to eat smaller meals, avoid high-fat foods during the first month, and report symptoms promptly rather than stopping the pen. A temporary four-week dose hold rather than full discontinuation often resolves GI intolerance while preserving the therapeutic relationship.

Pancreatitis is a rare but serious risk. The FDA label carries a warning to discontinue dulaglutide if pancreatitis is confirmed, and to avoid use in patients with a history of pancreatitis [1]. The absolute incidence of pancreatitis in REWIND was 0.7% in the dulaglutide arm versus 0.6% placebo (not statistically significant), which is reassuring for prescribers [2].

Heart rate increase of two to three beats per minute is a class effect of GLP-1 receptor agonists, including dulaglutide [1]. New Mexico patients with baseline tachycardia or known arrhythmia should have cardiac evaluation before starting.

Comparing Dulaglutide to Other GLP-1 Agents Available in New Mexico

New Mexico patients considering Trulicity often ask how it compares to semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) on cost and efficacy.

On glycemic efficacy, the AWARD-11 trial found that dulaglutide 4.5 mg reduced A1C by 1.87 percentage points from baseline at 36 weeks versus 1.21 percentage points for 1.5 mg [20]. The SUSTAIN-7 head-to-head trial comparing dulaglutide 1.5 mg to semaglutide 1 mg found semaglutide produced greater A1C reduction (1.5% vs. 1.1%) and greater weight loss (6.5 kg vs. 3.0 kg) over 40 weeks [21]. However, semaglutide 1 mg (Ozempic) carries a similar list price of approximately $935/month in 2026, so semaglutide's incremental efficacy does not come with a cost advantage.

Liraglutide (Victoza) costs approximately $660 to $700/month in New Mexico and requires daily injection versus Trulicity's once-weekly dosing, a practical consideration for adherence [3]. The LEADER trial (N=9,340) showed liraglutide reduced MACE by 13% versus placebo (HR 0.87 to 95% CI 0.78 to 0.97) [22], a cardiovascular effect size similar to REWIND's 12% relative risk reduction with dulaglutide.

For weight loss specifically, neither dulaglutide 1.5 mg nor 4.5 mg is FDA-approved for obesity management (BMI <27 or above). Semaglutide 2.4 mg (Wegovy) holds that indication and in STEP-1 (N=1,961) produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo [23]. New Mexico patients seeking primary weight management should discuss whether semaglutide or tirzepatide is more appropriate.

Practical Steps for New Mexico Patients in 2026

Paying $931 per month out of pocket for Trulicity is not the only option available to New Mexico residents. The sequence below reflects the most cost-effective path for most patients.

First, confirm the diagnosis and indication with a licensed prescriber, either in person or via telehealth. An A1C result above 7.0% with a type 2 diabetes diagnosis is the gateway for both insurance coverage and savings programs [7].

Second, check your insurance formulary before filling. Call the number on your insurance card and ask specifically: "Is dulaglutide on the formulary, what tier, and is a prior authorization required for type 2 diabetes?" Document the representative's name and the date.

Third, if you are commercially insured, enroll in the Lilly Savings Card at LillyCares.com before the first fill. The card is activated immediately and can reduce copays to $25/month [6].

Fourth, if you are uninsured and income-eligible, apply to the Lilly Cares Patient Assistance Program. Allow two to four weeks for processing and ask your FQHC patient navigator for help with documentation if needed [6].

Fifth, if a PA is required and denied, your prescriber should file an appeal citing the ADA 2024 guideline recommendation for GLP-1 agents in patients with type 2 diabetes and cardiovascular risk factors [7] and the REWIND cardiovascular outcomes data showing HR 0.88 for MACE reduction [2].

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen, independent of A1C" [7]. That direct quotation belongs in every PA appeal letter filed in New Mexico.

Sixth, if compounded dulaglutide is being considered, verify the compounding pharmacy's NM Board of Pharmacy 503A license number at the New Mexico Regulation and Licensing Department's online license lookup before signing any prescription [10].

The single most actionable step for most uninsured New Mexico patients with type 2 diabetes and an A1C above 7.5%: submit a Lilly Cares Foundation application this week. For commercially insured patients, activate the Lilly Savings Card before the first fill at the pharmacy counter, because it cannot be applied retroactively to a fill already processed.